Details

Autor(en) / Beteiligte

• Liu, Zhen
• Xiang, Liang
• Tian, Meng
• Wang, Haoyu
• Zhao, Xin
• Liu, Kangfei
• Yu, Jia
• Liu, Tianzhi
• Liu, Shangpeng
• Mu, Xin
• Yang, Bingxue
• Zhang, Shiyi
• Luo, Jie

Titel

A Counterion‐Free Strategy for Chronic Metabolic Acidosis Based on an Orally Administered Gut‐Restricted Inorganic Adsorbent

Ist Teil von

• Advanced materials (Weinheim), 2023-12, Vol.35 (51), p.e2305992-n/a

Ort / Verlag

Germany: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Chronic metabolic acidosis, arising as a complication of chronic kidney disease (CKD), not only reduces patients’ quality of life but also aggravates renal impairment. The only available therapeutic modality, involving intravenous infusion of NaHCO3, engenders undesirable sodium retention, thereby increasing hemodynamic load and seriously exacerbating the primary disease. This deleterious cascade extends to the development of cardiovascular diseases. Herein, an orally administered, gut‐restricted inorganic adsorbent that can effectively alleviate chronic metabolic acidosis without causing any electrolytic derangement or superfluous cardiovascular strain is developed. The genesis of ABC‐350 entails the engineering of bismuth subcarbonate via annealing, thereby yielding a partially β‐Bi2O3‐doped (BiO)2CO3 biphasic crystalline structure framework enriched with atomic vacancies. ABC‐350 can selectively remove chloride ions and protons from the gastrointestinal tract, mimicking the physiological response to gastric acid removal and resulting in increased serum bicarbonate. Owing to its gut‐restricted nature, ABC‐350 exhibits commendable biosafety, averting undue systemic exposure. In two rat models of metabolic acidosis, ABC‐350 emerges not only as a potent mitigator of acidosis but also effects discernible amelioration concerning proximal tubular morphology, interstitial fibrosis, and the incendiary cascades incited by metabolic acidosis. ABC‐350, as the translationally relevant material, provides a promising strategy for the treatment of metabolic acidosis. ABC‐350, an orally‐administered gut‐restricted adsorbent, is derived from bismuth subcarbonate annealing. It selectively adsorbs H+ and Cl− in the gastrointestinal tract, promoting HCO3− release into circulation to alleviate metabolic acidosis. This effect also delays renal damage, highlighting the potential for improved treatment outcomes.